Intercept Pharmaceuticals (ICPT) IPO opens for trading at $19.40, a 29% premium to its $15...


Intercept Pharmaceuticals (ICPT) IPO opens for trading at $19.40, a 29% premium to its $15 top-range IPO pricing. The company plans to use the funds to develop its lead drug candidate, obeticholic acid, which is a treatment for a rare autoimmune liver disease. The drug is a potential blockbuster for the company, and  is currently in Phase III trials.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs